CLINICAL TRIALS PROFILE FOR MISOPROSTOL

All Clinical Trials for Misoprostol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00097123 ↗	RCT of Misoprostol for Postpartum Hemorrhage in India	Completed	Bill and Melinda Gates Foundation	N/A	2002-09-01	Death rates for pregnant women in rural India are approximately forty-five times higher than in the United States. Bleeding after the birth of a child and underlying anemia are the primary causes of mothers' deaths and sickness in rural India. This study assesses the effectiveness of an oral drug, misoprostol, given in the late stage of labor to reduce the incidence of maternal bleeding following births assisted by midwives in selected sites in Belgaum District, Karnataka, India.
NCT00097123 ↗	RCT of Misoprostol for Postpartum Hemorrhage in India	Completed	Fogarty International Center of the National Institute of Health	N/A	2002-09-01	Death rates for pregnant women in rural India are approximately forty-five times higher than in the United States. Bleeding after the birth of a child and underlying anemia are the primary causes of mothers' deaths and sickness in rural India. This study assesses the effectiveness of an oral drug, misoprostol, given in the late stage of labor to reduce the incidence of maternal bleeding following births assisted by midwives in selected sites in Belgaum District, Karnataka, India.
NCT00097123 ↗	RCT of Misoprostol for Postpartum Hemorrhage in India	Completed	Global Network for Women's and Children's Health Research	N/A	2002-09-01	Death rates for pregnant women in rural India are approximately forty-five times higher than in the United States. Bleeding after the birth of a child and underlying anemia are the primary causes of mothers' deaths and sickness in rural India. This study assesses the effectiveness of an oral drug, misoprostol, given in the late stage of labor to reduce the incidence of maternal bleeding following births assisted by midwives in selected sites in Belgaum District, Karnataka, India.
NCT00097123 ↗	RCT of Misoprostol for Postpartum Hemorrhage in India	Completed	Jawaharlal Nehru Medical College	N/A	2002-09-01	Death rates for pregnant women in rural India are approximately forty-five times higher than in the United States. Bleeding after the birth of a child and underlying anemia are the primary causes of mothers' deaths and sickness in rural India. This study assesses the effectiveness of an oral drug, misoprostol, given in the late stage of labor to reduce the incidence of maternal bleeding following births assisted by midwives in selected sites in Belgaum District, Karnataka, India.
NCT00097123 ↗	RCT of Misoprostol for Postpartum Hemorrhage in India	Completed	John E. Fogarty International Center (FIC)	N/A	2002-09-01	Death rates for pregnant women in rural India are approximately forty-five times higher than in the United States. Bleeding after the birth of a child and underlying anemia are the primary causes of mothers' deaths and sickness in rural India. This study assesses the effectiveness of an oral drug, misoprostol, given in the late stage of labor to reduce the incidence of maternal bleeding following births assisted by midwives in selected sites in Belgaum District, Karnataka, India.
NCT00097123 ↗	RCT of Misoprostol for Postpartum Hemorrhage in India	Completed	National Cancer Institute (NCI)	N/A	2002-09-01	Death rates for pregnant women in rural India are approximately forty-five times higher than in the United States. Bleeding after the birth of a child and underlying anemia are the primary causes of mothers' deaths and sickness in rural India. This study assesses the effectiveness of an oral drug, misoprostol, given in the late stage of labor to reduce the incidence of maternal bleeding following births assisted by midwives in selected sites in Belgaum District, Karnataka, India.
NCT00097123 ↗	RCT of Misoprostol for Postpartum Hemorrhage in India	Completed	National Center for Complementary and Integrative Health (NCCIH)	N/A	2002-09-01	Death rates for pregnant women in rural India are approximately forty-five times higher than in the United States. Bleeding after the birth of a child and underlying anemia are the primary causes of mothers' deaths and sickness in rural India. This study assesses the effectiveness of an oral drug, misoprostol, given in the late stage of labor to reduce the incidence of maternal bleeding following births assisted by midwives in selected sites in Belgaum District, Karnataka, India.

Clinical Trial Conditions for Misoprostol

Condition Name

Condition Name for Misoprostol
Intervention	Trials
Postpartum Hemorrhage	43
Cervical Ripening	25
Pregnancy	22
Induction of Labor	19

Condition MeSH

Condition MeSH for Misoprostol
Intervention	Trials
Hemorrhage	102
Postpartum Hemorrhage	71
Abortion, Spontaneous	30
Abortion, Missed	27

Clinical Trial Locations for Misoprostol

Trials by Country

Trials by Country for Misoprostol
Location	Trials
United States	202
Egypt	125
France	17
India	13
Vietnam	12

Trials by US State

Trials by US State for Misoprostol
Location	Trials
California	25
Pennsylvania	19
New York	16
Texas	13
Massachusetts	12

Clinical Trial Progress for Misoprostol

Clinical Trial Phase

Clinical Trial Phase for Misoprostol
Clinical Trial Phase	Trials
PHASE4	6
PHASE3	3
PHASE2	1

Clinical Trial Status

Clinical Trial Status for Misoprostol
Clinical Trial Phase	Trials
Completed	267
Unknown status	63
Recruiting	54

Clinical Trial Sponsors for Misoprostol

Sponsor Name

Sponsor Name for Misoprostol
Sponsor	Trials
Gynuity Health Projects	61
Cairo University	43
Ain Shams University	27

Sponsor Type

Sponsor Type for Misoprostol
Sponsor	Trials
Other	672
Industry	22
NIH	12

Clinical Trials Update, Market Analysis, and Projection for Misoprostol

Last updated: October 25, 2025

---

Introduction

Misoprostol, a synthetic prostaglandin E1 analogue, plays an integral role in obstetrics, gynecology, and gastroenterology. Originally approved in the 1980s for gastric ulcer treatment, rapidly evolving indications now include medical abortion, labor induction, and off-label uses, positioning misoprostol as a critical asset in reproductive health. The ongoing development of new formulations and expanded indications continues to influence its global market landscape, driven by regulatory, technological, and socio-political factors.

---

Clinical Trials Landscape and Updates

Current Clinical Trials and Indications

Recent clinical trials underscore a trend toward refining misoprostol’s application in reproductive health, particularly for safety and efficacy in medical abortion and labor induction. Notably:

• Medical Abortion Efficacy: Multiple phase III studies validate the use of misoprostol alone or combined with mifepristone for early pregnancy termination, demonstrating high efficacy rates (≥95%) in various populations [1].

• Labor Induction Protocols: Trials conducted in North America and Asia assess optimal dosing regimens and delivery methods to improve safety profiles, especially in women with prior cesarean sections [2].

• Gastrointestinal Applications: While less active, ongoing studies continue to explore prolonged or modified formulations for gastric ulcer treatment, although these are less commercially prominent currently.

Regulatory Developments

Regulatory agencies worldwide are updating guidelines to facilitate access:

• FDA and EMA: While misoprostol is approved for gastric ulcers in many regions, specialized indications like abortion require off-label use or compassionate access programs. Recent efforts aim to streamline regulatory pathways for reproductive health indications.

• WHO Recommendations: The World Health Organization endorses misoprostol for obstetric hemorrhage and medical abortion, bolstering its acceptance across developing nations [3].

Emerging Technologies and Formulations

• Fixed-dose Combinations: Trials testing combined misoprostol-mifepristone formulations aim to improve compliance and reduce adverse events [4].

• Alternative Delivery Systems: Novel routes, including sublingual, buccal, and vaginal formulations, are under evaluation to enhance absorption and user convenience.

Market Analysis

Historical Market Dynamics

The global misoprostol market was valued at approximately USD 300 million in 2022, with significant contributions from North America, Europe, and Asia-Pacific. The expansion is driven by increased reliance on medical abortion protocols, especially in regions with restrictive surgical procedures [5].

Key Markets:

• North America: Dominates due to high awareness and regulatory acceptance, with expanded access through telemedicine during the COVID-19 pandemic.

• Europe: Although regulatory barriers exist, increased advocacy and WHO support bolster usage.

• Asia-Pacific: Fastest growth due to expanding reproductive health infrastructure and government support, notably India and China.

Drivers

• Rising Unmet Need for Safe Abortion: As restrictive laws persist in several jurisdictions, misoprostol remains a vital intervention [6].

• Healthcare Policy Shifts: Enhanced focus on maternal health and reduction of maternal mortality bolster demand for misoprostol for postpartum hemorrhage management.

• Patent Expiry & Generics: The expiration of key patents has led to a surge in generic manufacturing, lowering prices and increasing accessibility.

Challenges

• Regulatory and Ethical Barriers: Variable acceptance of medical abortion hampers uniform market expansion.

• Safety Controversies: Misuse and adverse events, particularly in unregulated settings, raise safety concerns, leading to regulatory tightening in some regions.

• Supply Chain Issues: Quality assurance and distribution barriers remain prevalent, especially in low-resource settings.

Market Projection Outlook

The market is projected to grow at a compound annual growth rate (CAGR) of approximately 8% over the next five years (2023-2028), driven by:

• Increased Adoption in Low- and Middle-Income Countries (LMICs): WHO's advocacy and international funding boost access.

• Innovative Formulations: The development of user-friendly delivery systems is expected to expand application and acceptance.

• Public Health Policies: Policies targeting maternal mortality reduction are refining protocols involving misoprostol.

• Regulatory Approvals for New Indications: Emerging clinical evidence may lead to formal approval for additional uses, fostering further market expansion.

Regional Market Forecast

• North America: Expected to maintain significant share due to regulatory acceptance and technological advances, with an estimated CAGR of 5%.

• Europe: Growth driven by policy reforms, with CAGR projected at 4-6%.

• Asia-Pacific: Represents the fastest growth segment, with a CAGR of approximately 10%, driven by expanding healthcare infrastructure and increasing awareness.

Key Entrants and Competitive Landscape

Major pharmaceutical companies like Ferring Pharmaceuticals, IPSEN, and generics producers dominate, benefiting from established manufacturing capacity and broad distribution networks. Strategic collaborations, licensing, and regional manufacturing are prevalent to meet local demand.

---

Strategic Implications for Stakeholders

• For Manufacturers: Focus on developing patient-centric formulations with ease of administration and improved safety profiles. Consider strategic alliances in emerging markets.

• For Regulators: Streamlined approval pathways, especially for new indications, can accelerate market growth and access.

• For Investors and Industry Analysts: The growing prevalence of contraindications in reproductive health suggests high potential, but market entry requires navigating complex legal and ethical landscapes.

---

Key Takeaways

• The clinical pipeline for misoprostol emphasizes safety and efficacy, particularly concerning reproductive health indications, underpinning future market growth.

• Regulatory flexibility and WHO endorsements are pivotal in expanding access, especially in LMICs.

• The market is poised for robust growth driven by innovative formulations, increasing adoption in emerging markets, and expanding indications.

• Competitive dynamics favor companies capable of navigating complex regulatory environments and deploying cost-effective, user-friendly products.

• Ethical considerations and safety concerns necessitate vigilant oversight to sustain market confidence.

---

FAQs

Q1: What are the primary current indications for misoprostol?
A1: Primarily used for preventing gastric ulcers, medical abortion, labor induction, and postpartum hemorrhage management.

Q2: How is the clinical development landscape shaping the future of misoprostol?
A2: Ongoing trials focus on optimized dosing, safety, new formulations, and expanded indications, potentially leading to wider regulatory approval and increased utilization.

Q3: Which regions are experiencing the fastest market growth for misoprostol?
A3: The Asia-Pacific region is projected to experience the fastest growth, driven by expanding healthcare infrastructure and supportive policies.

Q4: What challenges could hinder misoprostol market expansion?
A4: Regulatory barriers, safety concerns, unregulated supply chains, and ethical debates surrounding abortion use.

Q5: How do patent expirations influence the misoprostol market?
A5: Patent expiry enables generic manufacturing, which lowers prices and enhances accessibility, particularly in lower-income countries.

---

References

[1] ClinicalTrials.gov. (2022). Studies on Misoprostol Efficacy in Medical Abortion.
[2] World Health Organization. (2021). Guidelines for Misoprostol Use in Obstetrics.
[3] WHO. (2019). Recommendations on Medical Management of Pregnancy Termination.
[4] International Journal of Obstetrics & Gynecology. (2022). Fixed-dose Misoprostol-Mifepristone Formulations.
[5] MarketResearch.com. (2023). Global Misoprostol Market Report.
[6] Guttmacher Institute. (2021). Abortion Policy in LMICs and Access Dynamics.